Have any questions? 706-721-6582 or cts@augusta.edu
- (MEDLEY) A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children
Clinical Trial
(MEDLEY) A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children
This study is to test how safe and effective a new vaccine is for infants. It is a drug to prevent RSV (Respiratory Syncytial Virus) in high-risk neonates.
Eligibility Criteria
- Inclusion Criteria: 1. Perterm infants with a diagnosis of Chronic Lung Disease of Prematurity or with Congenital Heart Defect who are entering their first RSV season Exclusion Criteria: 1. Any fever (equal or greater than 100.4
RESEARCH. INNOVATION. DISCOVERY.